TD Cowen analyst Phil Nadeau has maintained their bullish stance on SNDX stock, giving a Buy rating on March 4.
Phil Nadeau has given his Buy rating due to a combination of factors indicating strong potential for Syndax Pharmaceuticals. The leukemia KOL panel discussion highlighted the anticipated broad adoption of Revuforj in treating r/r KMT2Ar and r/r NPM-1 acute leukemias within the year. Experts are optimistic about integrating menin inhibitors into the standard care for newly diagnosed patients, which could significantly enhance treatment outcomes.
Furthermore, the company’s management and surveyed physicians project a substantial uptake of Revuforj, with expectations that it will be used in a significant percentage of the r/r KMT2Ar and NPM-1m patient populations. The increase in the 2025 revenue estimate for Revuforj from $50MM to $75MM reflects the positive sentiment and early success of its launch. The potential for off-label use and the promising prospects in the 1L setting for unfit patients further support the Buy rating, as these factors suggest a strong market position and growth trajectory for Syndax Pharmaceuticals.
Nadeau covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Neurocrine, and BioMarin Pharmaceutical. According to TipRanks, Nadeau has an average return of 1.8% and a 40.42% success rate on recommended stocks.
In another report released on March 4, BTIG also reiterated a Buy rating on the stock with a $43.00 price target.